Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kadmon Holdings Llc (KDMN)

Kadmon Holdings Llc (KDMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,695,950
  • Shares Outstanding, K 178,521
  • Annual Sales, $ 8,290 K
  • Annual Income, $ -108,910 K
  • 60-Month Beta 1.13
  • Price/Sales 204.20
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KDMN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.72
  • Most Recent Earnings N/A on 11/04/21
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.16
  • Low Estimate -0.21
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.52 +11.50%
on 10/19/21
9.50 unch
on 11/08/21
+0.64 (+7.22%)
since 10/08/21
3-Month
4.63 +105.18%
on 08/18/21
9.50 unch
on 11/08/21
+4.52 (+90.76%)
since 08/06/21
52-Week
3.19 +197.34%
on 11/09/20
9.50 unch
on 11/08/21
+6.31 (+197.81%)
since 11/06/20

Most Recent Stories

More News
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third...

KDMN : 9.50 (+0.21%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGP, ESBK, KDMN, VNE; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Teekay LNG Partners L.P. (NYSE:TGP) concerning...

TGP : 16.98 (-0.06%)
ESBK : 23.08 (+0.04%)
KDMN : 9.50 (+0.21%)
VNE : 36.95 (+0.19%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

XLRN : 178.75 (-0.52%)
MRK : 131.95 (+0.15%)
JMP : 7.50 (+0.27%)
ECHO : 48.24 (+0.04%)
KDMN : 9.50 (+0.21%)
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein,...

KDMN : 9.50 (+0.21%)
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein,...

KDMN : 9.50 (+0.21%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MDLA, MSON, KDMN, ECHO; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Medallia, Inc. (NYSE: MDLA) concerning potential...

MDLA : 33.99 (+0.06%)
MSON : 26.54 (+4.74%)
KDMN : 9.50 (+0.21%)
ECHO : 48.24 (+0.04%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

GWB : 30.88 (-1.59%)
KDMN : 9.50 (+0.21%)
SIC : 14.49 (+0.07%)
TRIL : 18.44 (+2.62%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates JMP, KDMN, STMP, GPX; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

JMP : 7.50 (+0.27%)
KDMN : 9.50 (+0.21%)
STMP : 329.61 (unch)
GPX : 20.85 (unch)
Lifshitz Law Firm, P.C. Announces Investigation of CXP, HRC, KDMN, and JMP

NEW YORK, Sept. 11, 2021 (GLOBE NEWSWIRE) --

CXP : 19.28 (+0.10%)
HRC : 155.96 (+0.03%)
KDMN : 9.50 (+0.21%)
JMP : 7.50 (+0.27%)
KADMON HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kadmon Holdings, Inc. (NasdaqGS: KDMN) to Sanofi...

KDMN : 9.50 (+0.21%)
SNY : 48.60 (-1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Kadmon Holdings Inc. is a biopharmaceutical company. It discovers, develops and delivers transformative therapies for unmet medical needs. The company's product pipeline includes KD025, KD045 and KD033 which are in clinical satge. Kadmon Holdings Inc. is based in New York.

See More

Key Turning Points

3rd Resistance Point 9.53
2nd Resistance Point 9.51
1st Resistance Point 9.51
Last Price 9.50
1st Support Level 9.49
2nd Support Level 9.47
3rd Support Level 9.47

See More

52-Week High 9.50
Last Price 9.50
Fibonacci 61.8% 7.09
Fibonacci 50% 6.35
Fibonacci 38.2% 5.60
52-Week Low 3.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar